JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Board Members and Executives Engage in Share Transactions
- Novo Nordisk Reports Strong 2024 Earnings Growth
- Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations
- Unusually active option classes on open February 5th
- Novo Nordisk Reports Robust 2024 Growth and Strategic Acquisitions